JP2005512507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005512507A5 JP2005512507A5 JP2002588923A JP2002588923A JP2005512507A5 JP 2005512507 A5 JP2005512507 A5 JP 2005512507A5 JP 2002588923 A JP2002588923 A JP 2002588923A JP 2002588923 A JP2002588923 A JP 2002588923A JP 2005512507 A5 JP2005512507 A5 JP 2005512507A5
- Authority
- JP
- Japan
- Prior art keywords
- box
- biologically active
- hmg
- active fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101700047631 HMG Proteins 0.000 claims 21
- 102000018802 High Mobility Group Proteins Human genes 0.000 claims 20
- 102000004965 antibodies Human genes 0.000 claims 12
- 108090001123 antibodies Proteins 0.000 claims 12
- 102000005614 monoclonal antibodies Human genes 0.000 claims 11
- 108010045030 monoclonal antibodies Proteins 0.000 claims 11
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 7
- 230000000770 pro-inflamatory Effects 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 102000002222 HMGB1 Protein Human genes 0.000 claims 4
- 108010014739 HMGB1 Protein Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 210000004027 cells Anatomy 0.000 claims 4
- 102000000849 HMGB Proteins Human genes 0.000 claims 2
- 108010001860 HMGB Proteins Proteins 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000035693 Fab Effects 0.000 claims 1
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 1
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 210000002540 Macrophages Anatomy 0.000 claims 1
- 210000001616 Monocytes Anatomy 0.000 claims 1
- 210000000440 Neutrophils Anatomy 0.000 claims 1
- 101710040537 TNF Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 210000004962 mammalian cells Anatomy 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
Claims (19)
- ＨＭＧで処理された脊椎動物細胞からの前炎症性サイトカインの放出を阻害し得る、脊椎動物の高移動度群タンパク質（ＨＭＧ）Ｂボックスまたはその生物学的活性フラグメントに特異的に結合するがＨＭＧの非Ｂボックスエピトープには特異的に結合しないモノクローナル抗体。
- 請求項１記載のモノクローナル抗体を含有してなる、哺乳動物細胞からの前炎症性サイトカインの放出を阻害するための医薬組成物。
- 請求項１記載のモノクローナル抗体を含有してなる、炎症性サイトカインカスケードの活性化に特徴を有する患者における状態を処置するための医薬組成物。
- 該HMG Ｂボックスまたはその生物学的活性フラグメントが哺乳動物のHMG Ｂボックスまたはその生物学的活性フラグメントである、請求項１記載のモノクローナル抗体。
- 該哺乳動物のHMG Ｂボックスまたはその生物学的活性フラグメントがヒトのHMGＢボックスまたはその生物学的活性フラグメントである、請求項４記載のモノクローナル抗体。
- 該哺乳動物のHMG Ｂボックスまたはその生物学的活性フラグメントがHMG1 Ｂボックスまたはその生物学的活性フラグメントである、請求項４記載のモノクローナル抗体。
- 該HMG1 Ｂボックスまたはその生物学的活性フラグメントが、配列番号：５、配列番号：２０、配列番号：１６および配列番号：２３からなる群より選択されるアミノ酸配列を含有してなる、請求項６記載のモノクローナル抗体。
- 該脊椎動物細胞がマクロファージ、単球および好中球からなる群より選択される、請求項１記載のモノクローナル抗体。
- 該前炎症性サイトカインがTNF、IL-1βおよびIL-6からなる群より選択される、請求項１記載のモノクローナル抗体。
- 該抗体が、キメラ抗体、単鎖抗体またはFab抗体フラグメントである、請求項１記載のモノクローナル抗体。
- ＨＭＧで処理された脊椎動物細胞からの前炎症性サイトカインの放出を阻害し得るヒト化抗体である、脊椎動物の高移動度群タンパク質（ＨＭＧ）Ｂボックスまたはその生物学的活性フラグメントに特異的に結合するがＨＭＧの非Ｂボックスエピトープには特異的に結合しない単離された抗体。
- 該HMG Ｂボックスまたはその生物学的活性フラグメントが哺乳動物のHMG Ｂボックスまたはその生物学的活性フラグメントである、請求項１１記載の抗体。
- 該哺乳動物のHMG Ｂボックスまたはその生物学的活性フラグメントがヒトのHMGＢボックスまたはその生物学的活性フラグメントである、請求項１２記載の抗体。
- 該哺乳動物のHMG Ｂボックスまたはその生物学的活性フラグメントがHMG1 Ｂボックスまたはその生物学的活性フラグメントである、請求項１２記載の抗体。
- 該HMG1 Ｂボックスまたはその生物学的活性フラグメントが、配列番号：５、配列番号：２０、配列番号：１６および配列番号：２３からなる群より選択されるアミノ酸配列を含有してなる、請求項１４記載の抗体。
- i)HMG Bボックスまたはその生物学的活性フラグメントが配列番号：５または配列番号：２０の配列に対して少なくとも９０％同一であるアミノ酸配列を含有する、脊椎動物の高移動度群タンパク質（ＨＭＧ）Ｂボックスまたはその生物学的活性フラグメントに特異的に結合する；
ii) ＨＭＧの非Ｂボックスエピトープには特異的に結合しない；および
iii) ＨＭＧで処理された脊椎動物細胞からの前炎症性サイトカインの放出を阻害する、
モノクローナル抗体。 - 薬学的に許容され得る賦形剤中に請求項１、４〜１６いずれか記載の抗体を含有してなる組成物。
- 早期セプシスメディエイタのアンタゴニストをさらに含有してなる、請求項１７記載の組成物。
- 該HMG Bボックスまたはその生物学的活性フラグメントが配列番号：５または配列番号：２０の配列に対して少なくとも９０％同一であるアミノ酸配列を含有してなる、請求項１１記載の抗体。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29103401P | 2001-05-15 | 2001-05-15 | |
| US60/291,034 | 2001-05-15 | ||
| PCT/US2002/015329 WO2002092004A2 (en) | 2001-05-15 | 2002-05-15 | Use of hmg fragment as anti-inflammatory agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005512507A JP2005512507A (ja) | 2005-05-12 |
| JP2005512507A6 JP2005512507A6 (ja) | 2005-08-04 |
| JP2005512507A5 true JP2005512507A5 (ja) | 2007-08-02 |
Family
ID=23118552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002588923A Pending JP2005512507A (ja) | 2001-05-15 | 2002-05-15 | 抗炎症剤としてのｈｍｇフラグメントの使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20030060410A1 (ja) |
| EP (1) | EP1392844A4 (ja) |
| JP (1) | JP2005512507A (ja) |
| KR (1) | KR20040018370A (ja) |
| CN (1) | CN100447154C (ja) |
| AU (1) | AU2002309829B2 (ja) |
| BR (1) | BR0209689A (ja) |
| CA (1) | CA2447576C (ja) |
| CZ (1) | CZ20033402A3 (ja) |
| HU (1) | HUP0500042A3 (ja) |
| IL (3) | IL158643A0 (ja) |
| IS (1) | IS7037A (ja) |
| MX (1) | MXPA03010449A (ja) |
| NO (1) | NO20035087L (ja) |
| NZ (1) | NZ529423A (ja) |
| PL (1) | PL367132A1 (ja) |
| SK (1) | SK15422003A3 (ja) |
| WO (1) | WO2002092004A2 (ja) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7151082B2 (en) | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
| US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| US7754217B2 (en) * | 2001-03-16 | 2010-07-13 | Bio3 Research Srl | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| US7220723B2 (en) * | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| CN1671742A (zh) * | 2002-07-03 | 2005-09-21 | 塔博尔山圣拉弗尔基金中心 | Hmgb1在治疗组织损伤和/或促进组织修复中的用途 |
| US20060121047A1 (en) * | 2002-11-20 | 2006-06-08 | Tracey Kevin J | Use of hmgb polypetides for increasing immune responses |
| US20040156851A1 (en) * | 2002-11-20 | 2004-08-12 | Critical Therapeutics, Inc. | HMGB1 combination therapies |
| US20040141948A1 (en) * | 2002-11-20 | 2004-07-22 | Critical Therapeutics, Inc. | Use of HMGB fragments as anti-inflammatory agents |
| ATE378048T1 (de) * | 2002-12-06 | 2007-11-15 | The Feinstein Inst Medical Res | Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten |
| US20090069227A9 (en) * | 2003-04-29 | 2009-03-12 | Capogrossi Maurizio C | Use of HMGB1 to promote stem cell migration and/or proliferation |
| US7696169B2 (en) * | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| WO2005025604A2 (en) * | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
| WO2005026209A2 (en) * | 2003-09-11 | 2005-03-24 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
| EP1768698A4 (en) | 2004-06-17 | 2009-01-28 | Medimmune Inc | IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES |
| EP1814576A2 (en) * | 2004-07-20 | 2007-08-08 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
| WO2006012415A2 (en) | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Rage protein derivatives |
| WO2006024547A2 (en) * | 2004-09-03 | 2006-03-09 | Creabilis Therapeutics S.P.A. | Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use |
| CA2585043A1 (en) | 2004-10-22 | 2007-01-04 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
| US8129130B2 (en) | 2004-10-22 | 2012-03-06 | The Feinstein Institute For Medical Research | High affinity antibodies against HMGB1 and methods of use thereof |
| EP2364998A1 (en) | 2005-06-16 | 2011-09-14 | The Feinstein Institute for Medical Research | Antibodies against HMGB1 and fragments thereof |
| WO2007011606A2 (en) * | 2005-07-18 | 2007-01-25 | Critical Therapeutics, Inc. | USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS |
| US20100172909A1 (en) * | 2005-10-24 | 2010-07-08 | Masahiro Nishibori | Cerebral edema suppressant |
| JP3876325B1 (ja) * | 2005-10-24 | 2007-01-31 | 国立大学法人 岡山大学 | 脳梗塞抑制剤 |
| AU2006330807A1 (en) * | 2005-11-28 | 2007-07-05 | Medimmune, Llc | Antagonists of HMBG1 and/or rage and methods of use thereof |
| US7829097B2 (en) * | 2006-02-06 | 2010-11-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of HMGB1 for protection against ischemia reperfusion injury |
| JPWO2007102410A1 (ja) * | 2006-02-24 | 2009-07-23 | 国立大学法人金沢大学 | Ｒａｇｅポリペプチドの新規用途 |
| JP3882090B1 (ja) | 2006-05-19 | 2007-02-14 | 国立大学法人 岡山大学 | 脳血管攣縮抑制剤 |
| CA2663300C (en) * | 2006-09-15 | 2014-10-07 | Creabilis Therapeutics S.P.A. | Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1 |
| PT2068935E (pt) * | 2006-09-15 | 2011-07-08 | Creabilis Therapeutics S R L | Conjugados poliméricos de box-a de hmgb1 e variantes de box-a de hmgb1 |
| EP2123297A4 (en) * | 2007-02-15 | 2011-10-12 | Univ Kumamoto | THERAPEUTIC AGENT COMPRISING AN ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO HMGB-1 AS ACTIVE INGREDIENT |
| JP5285437B2 (ja) * | 2007-02-15 | 2013-09-11 | 学校法人福岡大学 | 抗ｈｍｇｂ−１抗体を含む臓器移植拒絶抑制剤 |
| EP2123299A4 (en) | 2007-02-15 | 2011-10-05 | Univ Kyushu Nat Univ Corp | THERAPEUTIC AGENT FOR INTERSTITIAL PULMONARY DISEASE COMPRISING ANTI-HMGB-1 ANTIBODY |
| BRPI0911513A2 (pt) | 2008-04-30 | 2016-07-12 | Genomix Co Ltd | métodos e agentes para coleta de células tronco da medula óssea funcionais in vivo com alta eficiência |
| JP5660889B2 (ja) | 2008-04-30 | 2015-01-28 | 株式会社ジェノミックス | 末梢循環への骨髄由来多能性幹細胞動員薬 |
| JP5467313B2 (ja) | 2009-09-28 | 2014-04-09 | 国立大学法人 岡山大学 | アテローム動脈硬化抑制剤 |
| BR112012009973A2 (pt) | 2009-10-28 | 2017-07-25 | Genomix Co Ltd | promotor de regeneração de tecido usando recrutamento de células-tronco mesenquimais da medula óssea e/ou células-tronco pluripotentes em sangue |
| HUE037157T2 (hu) | 2010-01-21 | 2018-08-28 | Univ Arkansas | Vakcinavektorok, és eljárások immunválaszok fokozására |
| MX350306B (es) | 2010-06-09 | 2017-09-04 | Univ Arkansas | Vacuna y metodos para reducir una infeccion por campylobacter. |
| EP2613797B1 (en) * | 2010-09-09 | 2015-11-04 | University Of Southern California | Compositions and methods for the removal of biofilms |
| CN114106139A (zh) | 2011-04-26 | 2022-03-01 | 斯特姆里姆有限公司 | 用于诱导组织再生的肽及其应用 |
| WO2012170742A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
| US9244074B2 (en) * | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
| PL2913058T3 (pl) | 2012-10-25 | 2018-04-30 | Genomix Co., Ltd. | Nowy sposób leczenia zawału mięśnia sercowego przy użyciu fragmentu HMGB1 |
| SG11201503215XA (en) | 2012-10-25 | 2015-06-29 | Genomix Co Ltd | Novel method for treating spinal cord injury using hmgb1 fragment |
| PL2956165T3 (pl) | 2013-02-14 | 2020-04-30 | The Board Of Trustees Of The University Of Arkansas | Kompozycje i sposoby wzmacniania odpowiedzi immunologicznych na Eimeria lub ograniczania infekcji Eimeria |
| EP3578190A1 (en) | 2013-03-15 | 2019-12-11 | The Board of Trustees of the University of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
| US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
| US9745366B2 (en) | 2013-09-23 | 2017-08-29 | University Of Southern California | Compositions and methods for the prevention of microbial infections |
| US11248040B2 (en) | 2013-09-26 | 2022-02-15 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
| US10233234B2 (en) | 2014-01-13 | 2019-03-19 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
| GB201508337D0 (en) | 2015-05-15 | 2015-06-24 | Hmgbiotech S R L | Novel peptides |
| US10940204B2 (en) | 2015-07-31 | 2021-03-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
| TWI758288B (zh) | 2016-05-03 | 2022-03-21 | 阿肯色州大學董事會 | 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法 |
| MX2019008949A (es) | 2017-01-27 | 2019-10-07 | Stemrim Inc | Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica. |
| JP2020513808A (ja) | 2017-03-15 | 2020-05-21 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法 |
| US11298403B2 (en) | 2017-12-01 | 2022-04-12 | StemRIM Inc. | Therapeutic agent for inflammatory bowel disease |
| CN113203857B (zh) * | 2021-05-06 | 2021-12-31 | 上海奕检医学检验实验室有限公司 | 一种肿瘤诊断试剂盒 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US144201A (en) * | 1873-11-04 | Improvement in volute springs | ||
| US53841A (en) * | 1866-04-10 | Improvement in measuring-funnels | ||
| US60410A (en) * | 1866-12-11 | newman | ||
| JPS62166897A (ja) * | 1986-01-20 | 1987-07-23 | Toyo Soda Mfg Co Ltd | 核内非ヒストン蛋白質に対するモノクロ−ナル抗体 |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| GB9217316D0 (en) * | 1992-08-14 | 1992-09-30 | Ludwig Inst Cancer Res | Schwann cell mitogenic factor,its preparation and use |
| JP3472048B2 (ja) * | 1995-10-09 | 2003-12-02 | 鐘淵化学工業株式会社 | 自己免疫疾患の診断薬 |
| US6323329B1 (en) * | 1995-12-21 | 2001-11-27 | Jorn Bullerdiek | Nucleic acid sequences of genes encoding high mobility group proteins |
| US6171779B1 (en) * | 1996-07-12 | 2001-01-09 | University Of Medicine & Dentistry Of New Jersey | HMGI proteins in cancer |
| US6720472B2 (en) * | 1996-07-12 | 2004-04-13 | University Of Medicine And Dentistry Of New Jersey | HMGI proteins in cancer and obesity |
| EP1577671A1 (en) * | 1996-07-17 | 2005-09-21 | Kaneka Corporation | Diagnostic drugs for autoimmune diseases |
| US20030032090A1 (en) * | 1997-05-07 | 2003-02-13 | Schering Corporation, A New Jersey Corporation | Human receptor proteins; related reagents and methods |
| US20030027260A1 (en) * | 1997-10-17 | 2003-02-06 | Genentech, Inc. | Human Toll homologues |
| US6228642B1 (en) | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
| US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| US7151082B2 (en) * | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
| US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| US6677321B1 (en) * | 1999-12-09 | 2004-01-13 | Bruce Levin | Methods and compositions for treatment of inflammatory disease |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| WO2002000677A1 (en) * | 2000-06-07 | 2002-01-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US7754217B2 (en) * | 2001-03-16 | 2010-07-13 | Bio3 Research Srl | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| US20030032674A1 (en) * | 2001-08-13 | 2003-02-13 | Hwang Daniel H. | Use of unsaturated fatty acids to treat severe inflammatory diseases |
| JP2003052763A (ja) * | 2001-08-16 | 2003-02-25 | Paramount Bed Co Ltd | ベッドにおける側柵 |
-
2002
- 2002-05-15 BR BR0209689-7A patent/BR0209689A/pt not_active Application Discontinuation
- 2002-05-15 PL PL02367132A patent/PL367132A1/xx not_active Application Discontinuation
- 2002-05-15 WO PCT/US2002/015329 patent/WO2002092004A2/en active Application Filing
- 2002-05-15 CZ CZ20033402A patent/CZ20033402A3/cs unknown
- 2002-05-15 HU HU0500042A patent/HUP0500042A3/hu unknown
- 2002-05-15 MX MXPA03010449A patent/MXPA03010449A/es active IP Right Grant
- 2002-05-15 AU AU2002309829A patent/AU2002309829B2/en not_active Ceased
- 2002-05-15 CN CNB028120388A patent/CN100447154C/zh not_active Expired - Fee Related
- 2002-05-15 NZ NZ529423A patent/NZ529423A/en not_active IP Right Cessation
- 2002-05-15 US US10/147,447 patent/US20030060410A1/en not_active Abandoned
- 2002-05-15 KR KR10-2003-7014914A patent/KR20040018370A/ko not_active Application Discontinuation
- 2002-05-15 EP EP02736852A patent/EP1392844A4/en not_active Withdrawn
- 2002-05-15 SK SK1542-2003A patent/SK15422003A3/sk unknown
- 2002-05-15 CA CA2447576A patent/CA2447576C/en not_active Expired - Fee Related
- 2002-05-15 IL IL15864302A patent/IL158643A0/xx unknown
- 2002-05-15 JP JP2002588923A patent/JP2005512507A/ja active Pending
-
2003
- 2003-06-06 US US10/456,949 patent/US20040005316A1/en not_active Abandoned
- 2003-10-28 IL IL158643A patent/IL158643A/en not_active IP Right Cessation
- 2003-11-14 NO NO20035087A patent/NO20035087L/no not_active Application Discontinuation
- 2003-11-14 IS IS7037A patent/IS7037A/is unknown
-
2010
- 2010-10-24 IL IL208892A patent/IL208892A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005512507A5 (ja) | ||
| JP2006510619A5 (ja) | ||
| AP690A (en) | Immunomodulators based on a polypeptide other than human interleukin 10. | |
| DK2330129T3 (en) | ANTI-TNF ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS | |
| HRP20180941T1 (hr) | Protutijela protiv il-17 | |
| JP2003507364A5 (ja) | ||
| JP2009539349A5 (ja) | ||
| JP2012087144A (ja) | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 | |
| AU2007351514A1 (en) | Interleukin -13 binding proteins | |
| BRPI0113420B1 (pt) | Anticorpos para il-1beta humano | |
| EP1644416A2 (en) | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses | |
| EP1720573A2 (en) | Methods and compositions for treating il-13 related pathologies | |
| WO1991002078A1 (en) | Tumour necrosis factor binding ligands | |
| SK1152003A3 (en) | Dual specificity antibodies and methods of making and using | |
| WO2006039470A2 (en) | Anti- amyloid antibodies, compositions, methods and uses | |
| JP2012504602A5 (ja) | ||
| CA2451680A1 (en) | Human dr4 antibodies and uses thereof | |
| JP2005516606A5 (ja) | ||
| KR19990077344A (ko) | 합성 il-10 동족체 | |
| JP2023081303A5 (ja) | ||
| JP2005502319A5 (ja) | ||
| US20070042963A1 (en) | Therapeutic peptides | |
| WO2003047510A2 (en) | Anti-tnf antibodies, compositions, methods and uses | |
| CA2090401A1 (en) | Method of treating viral infection | |
| JP2003516940A5 (ja) |